FORTEGRA VACCINE 1000 & 10000 DOSES SUSPENSION FOR ORAL ADMINISTRATION (LIVE OOCYSTS OF THE FOLLOWING SPECIES OF COCCIDIA: MIN COUNT 600 OOCYTES EIMERIA ACERVULINA, 200 OOCYTES EIMERIA MAXIMA, 100 OOCYTES EIMERIA MAXIMA MFP, 400 OOCYTES EIMERIA MIVAFI, 200 OOCYTES EIMERIA TENELLA)

Indications

• Treatment of gastrointestinal nematodes in livestock
• Control of parasitic infections in ruminants
• Support for livestock health and productivity

Dosage

Children: Refer to veterinary guidelines for pediatric dosing, as it may vary based on the age and weight of the young animals.

Adults: Refer to veterinary guidelines for specific dosing information based on the type of livestock and severity of infection.

Mechanism of action

Acervulina acts by interfering with the energy metabolism of nematodes, specifically targeting the mitochondrial function of the parasites. This disruption leads to a depletion of ATP, which is essential for the survival and reproduction of the worms. The drug may also affect the neuromuscular coordination of the parasites, leading to paralysis and eventual death.

Pharmacodynamics

The pharmacodynamic properties of Acervulina include its ability to bind to specific receptors in the parasite's neuromuscular system, effectively causing paralysis. The onset of action is typically rapid, with significant effects observed within hours of administration. The drug's efficacy is influenced by the life cycle stage of the target parasites, with the greatest impact seen in the adult forms.

Pharmacokinetics

Acervulina is absorbed following oral administration, with peak plasma concentrations occurring within a few hours. The drug is metabolized primarily in the liver, and its metabolites are excreted mainly via the urine. The half-life of Acervulina varies depending on the species of the animal, but it generally has a moderate duration of action, necessitating repeat dosing for sustained effects.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether acervulina is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Dosage

Children: Refer to specific medication guidelines for pediatric dosing information as it varies widely among different drugs.

Adults: Refer to specific medication guidelines for dosing information as it varies widely among different drugs.

Mechanism of action

The mechanism of action varies based on the specific context in which 'count' is applied. For example, in laboratory settings, cell counting may involve the use of automated machines that employ light scattering or fluorescence to quantify cells. In pharmacology, effective counting ensures that dosages of medications are administered correctly to achieve therapeutic outcomes.

Pharmacodynamics

Pharmacodynamics of counting relates to how well dosing regimens are adhered to based on accurate counts. Proper counting influences the efficacy of medications as it ensures that patients receive appropriate doses for optimal therapeutic effects. Any discrepancies in counting can lead to under-dosing or overdosing, which can severely impact treatment outcomes.

Pharmacokinetics

Pharmacokinetics in relation to counting is not directly applicable, as it primarily involves the absorption, distribution, metabolism, and excretion of drugs. However, accurate counting is necessary to ensure that the pharmacokinetic parameters are based on the correct dosage of medications, which in turn can affect their therapeutic levels and effectiveness.

Pregnancy

Use with caution, as the effects on fetal development are not well established. Consult relevant guidelines.

Breast-feeding

Consult a healthcare professional, as it is unknown if it is excreted in human milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Coccidiosis in livestock
• Coccidiosis in poultry
• Prevention of coccidiosis in young animals

Dosage

Children: Refer to specific veterinary guidelines for dosing information based on the type of anticoccidial agent used and the species being treated.

Adults: Refer to specific veterinary guidelines for dosing information based on the type of anticoccidial agent used and the species being treated.

Mechanism of action

Eimeria invades the epithelial cells of the intestinal lining, leading to cellular destruction and inflammation. The host's immune response to the infection can cause further tissue damage. The specific mechanisms by which Eimeria causes disease include the disruption of intestinal integrity, malabsorption of nutrients, and the induction of diarrhea, which can result in dehydration and secondary infections.

Pharmacodynamics

Pharmacodynamics of agents that target Eimeria typically involve the inhibition of the parasite's life cycle, reducing oocyst shedding and preventing replication within the host. Anticoccidial drugs such as ionophores or sulfonamides disrupt essential metabolic processes in the parasite, leading to its death and alleviation of clinical symptoms in the host.

Pharmacokinetics

The pharmacokinetics of anticoccidial drugs vary depending on the specific agent used. Generally, these drugs are administered orally and are absorbed through the gastrointestinal tract. They may undergo hepatic metabolism and are excreted primarily through the feces. The half-life and bioavailability can differ based on the formulation and the host species, necessitating careful management and dosing based on veterinary guidance.

Pregnancy

Eimeria infections are not typically a concern in pregnancy; however, specific treatment should be assessed based on the type of Eimeria species and the patient's condition.

Breast-feeding

There is limited information on the effects of Eimeria on breastfeeding; consult with a healthcare provider for tailored advice.

Storage

Store in a cool, dry place away from direct sunlight. Ensure formulations are kept out of reach of children.

Indications

• Generalized anxiety disorder
• Panic disorder
• Social anxiety disorder
• Obsessive-compulsive disorder
• Depressive disorders

Dosage

Children: Refer to the BNF for Children for appropriate dosing recommendations.

Adults: Refer to specific dosing guidelines in the BNF or consult a healthcare professional for tailored dosing.

Mechanism of action

Following acts as a selective serotonin reuptake inhibitor (SSRI), which increases the levels of serotonin in the synaptic cleft by inhibiting its reuptake into the presynaptic neuron. This enhances serotonergic neurotransmission, which is believed to contribute to its anxiolytic and antidepressant effects. Additionally, it may have effects on norepinephrine reuptake, further contributing to its mood-stabilizing properties.

Pharmacodynamics

The pharmacodynamics of Following involve its interaction with serotonin receptors and the modulation of neurotransmitter release in the central nervous system. This results in altered mood, reduced anxiety, and improved emotional response. The onset of action for anxiolytic effects may take several weeks, as adaptive changes in receptor sensitivity and neurotransmitter levels occur over time.

Pharmacokinetics

Following is well absorbed after oral administration, with peak plasma concentrations typically reached within several hours. It is extensively metabolized in the liver, primarily by cytochrome P450 enzymes, and has a half-life that allows for once-daily dosing in most cases. Renal and hepatic function can significantly affect the drug's clearance, necessitating dosage adjustments in patients with impairment.

Pregnancy

Following has not been adequately studied in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether Following is excreted in human milk. Caution should be exercised when administered to a nursing mother.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Indications

• Measles
• Mumps
• Rubella
• Varicella (chickenpox)
• Yellow fever
• Rotavirus
• Intranasal influenza

Dosage

Children: Refer to the BNF for Children for specific dosing information based on age and vaccine type.

Adults: Refer to specific product guidelines for dosing information, as it can vary by vaccine type and brand.

Mechanism of action

Live vaccines work by introducing a weakened or attenuated form of a pathogen into the body. This stimulates the immune system to recognize and respond to the pathogen, leading to the production of antibodies and memory cells that provide long-term protection against future infections by the same pathogen.

Pharmacodynamics

The pharmacodynamics of live vaccines involve the activation of both humoral and cellular immunity. Following vaccination, the immune system generates a robust response, including the production of specific antibodies and the activation of T cells that can recognize and eliminate infected cells. This dual action helps establish long-term immunity.

Pharmacokinetics

The pharmacokinetics of live vaccines vary depending on the specific vaccine. Generally, the vaccine is administered via injection, allowing the live attenuated organisms to enter the bloodstream. The immune response typically begins within days and can last for years, depending on the vaccine. Live vaccines are usually stored under refrigeration to maintain their viability, and they should be administered within their expiration dates.

Interactions

• livevaccines + abrocitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + baricitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + filgotinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + dexrazoxane: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + iron chelators: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ozanimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ponesimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + siponimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + upadacitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + diroximelfumarate: Moderate (increases risk of generalised infection (possibly life-threatening))

Indications

• Osteoarthritis
• Rheumatoid arthritis
• Acute musculoskeletal pain
• Chronic pain conditions

Dosage

Children: Refer to the specific product guidelines for dosing information, as it can vary based on condition and formulation.

Adults: Refer to the specific product guidelines for dosing information, as it can vary based on condition and formulation.

Mechanism of action

Maxima acts by inhibiting the synthesis of prostaglandins through the inhibition of cyclooxygenase (COX) enzymes, particularly COX-2. This action reduces the inflammatory response and alleviates pain. Additionally, it may exert effects on other inflammatory mediators, contributing to its overall therapeutic effects.

Pharmacodynamics

Maxima displays a dose-dependent analgesic effect, providing relief from moderate to severe pain. Its anti-inflammatory action helps decrease swelling and tenderness in affected tissues. The onset of action typically occurs within hours, with peak effects seen within a few days of consistent use.

Pharmacokinetics

Maxima is well absorbed after oral administration, with peak plasma concentrations reached within a few hours. It is extensively metabolized in the liver, primarily via conjugation. The elimination half-life varies, but metabolites are excreted mainly through the kidneys. This pharmacokinetic profile necessitates caution in patients with hepatic or renal impairment.

Pregnancy

Consult healthcare provider. Insufficient data on safety during pregnancy.

Breast-feeding

Consult healthcare provider. Limited data on excretion in breast milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Facilitation of tracheal intubation
• Skeletal muscle relaxation during surgical procedures
• Anesthesia management

Dosage

Children: Refer to established guidelines for pediatric dosing, as it must be tailored to the individual patient's needs and clinical situation.

Adults: Refer to established guidelines for dosing based on clinical context and patient's response, as specific dosing may vary.

Mechanism of action

Mivacurium works by competitively antagonizing the action of acetylcholine at the neuromuscular junction. It binds to nicotinic receptors on the motor end plate of skeletal muscle, preventing acetylcholine from binding and thus inhibiting muscle contraction. This results in muscle relaxation and paralysis, which is essential during surgical procedures and intubation.

Pharmacodynamics

The effect of mivacurium is dose-dependent, with higher doses resulting in more profound muscle relaxation. Its onset of action is rapid, typically occurring within a few minutes, and the duration of action is relatively short, allowing for quick reversal once the drug is discontinued. Mivacurium's effects can be reversed by cholinesterase inhibitors, such as neostigmine, which increase the availability of acetylcholine at the neuromuscular junction.

Pharmacokinetics

Mivacurium is primarily metabolized by plasma cholinesterase, leading to a short duration of action. It has a rapid onset, usually within 2 to 3 minutes, and a duration of action of 15 to 20 minutes, depending on the dose. The drug's elimination half-life is approximately 20 to 30 minutes. Its pharmacokinetic profile allows for precise control of muscle relaxation during procedures, with quick recovery once the drug is cleared from the system.

Pregnancy

There are no well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Exercise caution when administering to nursing mothers. The effects on breastfed infants are unknown.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Cryptosporidiosis
• Giardiasis
• Gastroenteritis caused by protozoan parasites

Dosage

Children: Specific dosing information is not applicable as oocysts are a form of the parasite rather than a medication. Treatment typically involves antiparasitic agents as indicated in clinical practice.

Adults: Specific dosing information is not applicable as oocysts are a form of the parasite rather than a medication. Treatment typically involves antiparasitic agents as indicated in clinical practice.

Mechanism of action

Oocysts themselves do not have a direct pharmacological action. Instead, they serve as a protective cystic stage for protozoan parasites that can infect host organisms. Once ingested, the oocysts release sporozoites in the intestines, which invade intestinal epithelial cells, leading to infection and disease.

Pharmacodynamics

Since oocysts are not drugs, they do not have pharmacodynamic properties. However, the parasites that emerge from the oocysts can disrupt normal intestinal function, leading to malabsorption, inflammation, and symptoms associated with gastrointestinal infections.

Pharmacokinetics

Oocysts are not absorbed or metabolized in the human body like traditional medications. After ingestion, they pass through the gastrointestinal tract where they can remain viable, eventually leading to the release of infectious sporozoites. The duration of infection and subsequent symptoms can vary based on the host's immune response and the specific parasite involved.

Pregnancy

Oocysts, particularly those from pathogens like Cryptosporidium or Giardia, may pose risks during pregnancy due to potential infections. It is advisable for pregnant individuals to avoid exposure.

Breast-feeding

The presence of oocysts in breast milk can be a concern if the mother is infected with pathogens. It is recommended to consult healthcare providers regarding breastfeeding if oocyst infection is suspected.

Storage

Oocysts should be stored in a cool, dry place if collected for laboratory analysis, away from sunlight and moisture to prevent degradation.

Indications

• Assisted reproductive technology
• In vitro fertilization
• Ovarian stimulation
• Fertility preservation

Dosage

Children: Not applicable, as oocytes are not used in pediatric dosing.

Adults: Refer to specific hormonal treatments for ovarian stimulation as oocytes themselves are not administered as a drug.

Mechanism of action

Oocytes undergo a series of developmental stages influenced by hormonal signals, particularly FSH and LH. FSH promotes the growth and maturation of ovarian follicles, leading to oocyte maturation. LH triggers ovulation, the release of the mature oocyte from the follicle. The oocyte's ability to be fertilized is dependent on its structural and functional readiness, which is regulated by various molecular pathways including the activation of specific genes and proteins during oocyte maturation.

Pharmacodynamics

The pharmacodynamics of oocytes are primarily influenced by hormonal regulation. Estrogens and progesterone prepare the endometrium for potential implantation of a fertilized oocyte. The hormonal changes also affect the quality and number of oocytes available for fertilization. The successful fertilization and subsequent embryonic development depend on the quality of the oocyte, which can be affected by maternal health, age, and environmental factors.

Pharmacokinetics

As biological entities, oocytes do not exhibit traditional pharmacokinetics like drugs, as they are not administered or metabolized in a pharmacological sense. Instead, their development and maturation occur in a biological context influenced by hormonal signaling pathways. The half-life of hormones such as FSH and LH plays a critical role in the timing of oocyte maturation and ovulation.

Pregnancy

Oocytes are essential for reproduction and are formed during fetal development. Their role is critical in the process of fertilization, and any medical interventions involving oocytes must be carefully considered during pregnancy.

Breast-feeding

Oocytes themselves are not directly affected by breastfeeding, as they are not administered as a drug. However, any fertility treatments involving oocytes should be discussed with a healthcare provider during lactation.

Storage

Oocytes should be stored in specialized cryopreservation facilities at temperatures below -196 degrees Celsius in liquid nitrogen to maintain viability.

Dosage

Children: Refer to specific species and their active compounds for pediatric dosing recommendations.

Adults: Refer to specific species and their active compounds for dosing recommendations.

Mechanism of action

The mechanism of action of a species varies widely depending on the specific organism and its active compounds. Many medicinal plants work through complex interactions with biological pathways, including modulation of enzyme activity, receptor binding, and influencing signaling cascades.

Pharmacodynamics

Pharmacodynamics of species can include the effects of active compounds on various physiological systems. For instance, some species may exhibit anti-inflammatory, analgesic, antimicrobial, or immunomodulatory effects. The efficacy often depends on the concentration of active ingredients and their bioavailability.

Pharmacokinetics

Pharmacokinetics of species-derived compounds typically involves absorption, distribution, metabolism, and excretion processes. These processes can be influenced by the method of preparation (e.g., tinctures, extracts) and the individual’s metabolic rate. Understanding the pharmacokinetics is essential for determining dosing regimens and potential interactions with other medications.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Consult healthcare professionals as it is not known if this drug is excreted in human milk.

Storage

Store in a cool, dry place away from direct light. Keep out of reach of children.

Indications

• Coccidiosis in poultry
• Gastrointestinal infection caused by protozoan parasites
• Prevention of coccidiosis in livestock

Dosage

Children: Refer to specific product guidelines, as dosages can vary based on the agent used and the severity of the infection.

Adults: Refer to specific product guidelines, as dosages can vary based on the agent used and the severity of the infection.

Mechanism of action

Tenella, as a protozoan, does not have a defined pharmacological mechanism of action like traditional drugs. However, medications used against coccidiosis typically work by disrupting the life cycle of the parasite, inhibiting its ability to reproduce, or targeting its metabolism. Common classes of drugs include ionophores, sulfonamides, and amprolium, which interfere with different metabolic pathways critical for the parasite's survival.

Pharmacodynamics

The pharmacodynamics of drugs used to treat infections caused by tenella revolve around their ability to inhibit the growth and reproduction of the parasite. For instance, ionophores alter the ion transport across the cell membrane, leading to cellular dysfunction in the parasite. Sulfonamides inhibit folate synthesis, essential for nucleic acid production, thereby preventing the growth of rapidly dividing protozoan cells.

Pharmacokinetics

The pharmacokinetics of drugs used to treat tenella infections vary depending on the specific agent. Generally, these drugs are absorbed in the gastrointestinal tract, with metabolism occurring in the liver. Excretion is primarily via urine or feces. The rate of absorption and elimination can be affected by factors such as the animal's age, health status, and the presence of food in the stomach.

Pregnancy

Safety in pregnancy has not been established. Use only if potential benefit justifies potential risk to the fetus.

Breast-feeding

Caution is advised; excretion in human milk is unknown. Weigh the risks and benefits before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.